trending Market Intelligence /marketintelligence/en/news-insights/trending/qdcBGFgIp-mDD1qry9Mv1w2 content esgSubNav
In This List

Minerva ends development of depression drug after mid-stage study failure

Blog

Post-webinar Q&A: Global Credit Risk Trends 2021 and Beyond

Blog

University Essentials: From Crisis to Resilience – Navigating Sustainable Recovery

Blog

EV impact; vaccines to boost job market; coal supply constraints

Blog

Shore Capital is Now Available in S&P Global’s Aftermarket Research Collection


Minerva ends development of depression drug after mid-stage study failure

Minerva Neurosciences Inc.'s depression treatment MIN-117 failed to significantly reduce symptoms of depression compared to placebo in patients with major depressive disorder during a mid-stage study.

The Waltham, Mass.-based biotechnology company was evaluating 2.5-milligram and 5-milligram doses of the drug in adult patients with moderate to severe major depressive disorder in the six-week phase 2b trial.

Both doses of the drug failed to reduce symptoms of anxiety over the six-week treatment period.

Minerva Executive Chairman and CEO Remy Luthringer expressed disappointment with the results and said the company has no plans to further develop the drug in the major depressive disorder indication.